Charles River and Lundbeck sign an agreement to use Logica to advance the discovery of novel neurological drugs.
WILMINGTON, Mass., October 03, 2024--Charles River previews SfN 2024, including the latest developments in CNS research and innovative approaches to tackling neurodegenerative disorders.
WILMINGTON, Mass., October 02, 2024--Charles River and Lundbeck enter agreement to utilize AI-powered Logica to advance the discovery of novel drugs for neurological disease.